NRG Oncology NCORP Research Base

Project: Research project

Project Details


The purpose of this project is to validate the Disease-Related Symptoms-Physical (DRS-P) subscale of the 18-item NCCN FACT-Ovarian Symptom Index (NFOSI-18) as a clinical trial outcome tool for patients with advanced ovarian cancer. The NFOSI-18 is an ovarian cancer-specific symptom index comprised of symptoms rated as highest priority by both oncology clinical experts and women with advanced ovarian cancer. We propose to conduct statistical analyses of data from GY004, a Phase III clinical trial conducted by NRG Oncology comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. These analyses will include examination of the correlation between the DRS-P and other subscales, and assessment of sensitivity to treatment and responsiveness over time. Item level analysis will also be conducted on the DRS-P to identify those items that are more responsive to change than others, leading to improved measurement.
Effective start/end date8/1/207/31/21


  • NRG Oncology Foundation, Inc. (NCORP-CELLA-GY7//2UG1CA89867-07)
  • National Cancer Institute (NCORP-CELLA-GY7//2UG1CA89867-07)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.